BUZZ-Revolution Medicines shares fall after Incyte announces competitive pancreatic cancer data

October 26 - ** Revolution Medicines (RVMD.O) shares fell 1%, closing at $185.06

** Incyte (INCY.O) announced at the ESMO conference that its KRAS G12D-targeted drug zecdarasib achieved an objective response rate of 89% in pancreatic cancer research; RBC Capital Markets analysts said the result is overall competitive with Revolution Medicines' zoldonrasib, but no significant differences have yet emerged

** Both companies are developing similar drugs targeting KRAS G12D mutant pancreatic cancer, making them major competitors in this field

** RBC stated that Incyte's pancreatic cancer data showed no major surprises, with objective response rate and safety basically in line with expectations and comparable to data previously reported by Revolution

** The brokerage noted that Incyte’s zecdarasib is still on a comparable development timeline and is expected to announce late-stage pancreatic cancer clinical data in 2028

** RBC said the two companies remain “neck and neck,” and long-term survival data will likely determine the eventual winner

** Taking intraday fluctuations into account, RVMD's share price has doubled so far this year

(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack needed context, Reuters does not guarantee the accuracy of these automated translations and provides them only for readers' convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation features.)